Financial Data and Key Metrics - Total revenues for Q3 2024 were $294 million, a 9% year-over-year improvement, at the upper end of the guidance range [19] - Adjusted EBITDA for Q3 2024 was $105 million, or 36% of revenues, an improvement of $85 million versus the prior year [19] - Year-to-date revenue was $849 million, up 10% versus the prior year, driven by U.S. government and international medical countermeasures [24] - Year-to-date adjusted EBITDA was $162 million, an improvement of $188 million versus the prior year [24] - Net debt was reduced to $551 million, a $206 million reduction since the beginning of 2024 [17] Business Line Performance - NARCAN sales were $95 million in Q3 2024, with year-to-date volumes up 7% [18][20] - Anthrax MCM sales were $11 million, a decrease versus the prior year due to timing of deliveries [21] - Smallpox MCM sales were $133 million, including deliveries of ACAM2000 and VIGIV contract options to the U.S. government [21] - Other product sales, including BAT, were $30 million, and Bioservices revenues were $14 million [21] Market Performance - NARCAN volumes increased year-to-date, driven by strong demand in the U.S. public interest channel and expanded categories like business and retail channels [11][31] - The company received FDA approval for ACAM2000 to include the mpox expanded indication, strengthening its smallpox portfolio [11][36] - The company secured over $500 million in medical countermeasure contract modifications for Anthrax MCM, Smallpox MCM, and BAT [18] Strategic Direction and Industry Competition - The company is transitioning from the stabilization phase to the turnaround phase of its multi-year plan, focusing on operational improvements and profitable growth [7][8] - The company is strategically focusing on international expansion and line extensions of current products, such as NARCAN, to drive future growth [39] - The company is leveraging its unique position in medical countermeasures to engage with U.S. and international governments, responding to public health threats like mpox and Ebola [35][37] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the bipartisan support for the company's mission to combat public health threats like opioid overdoses and biodefense [13] - The company raised its 2024 revenue and adjusted EBITDA guidance, reflecting strong performance and improved financial stability [9][25] - Management highlighted the importance of maintaining competitive pricing for NARCAN while leveraging its brand and distribution capabilities to sustain market leadership [57][58] Other Important Information - The company successfully refinanced its debt, closing a $250 million term loan with Oak Hill Advisors and a $100 million asset-backed revolving credit facility with Wells Fargo [10][16] - The company resolved legacy compliance and legal matters, including a $50 million settlement with Janssen Pharmaceuticals [15] - The company appointed Dr. Simon Lowry as Head of R&D and Chief Medical Officer, and promoted Jessica Perl to General Counsel and Corporate Secretary [12] Q&A Session Summary Question: Long-term gross margin outlook for NARCAN - The company expects NARCAN gross margins to stabilize around the current level of 50%, with ongoing efforts to improve cost of goods sold [45] Question: New growth opportunities and asset acquisitions - The company is focused on both internal growth opportunities, such as NARCAN line extensions and geographic expansion, and external business development deals that align with its capabilities [47][51] Question: Factors impacting NARCAN guidance and competitive dynamics - NARCAN guidance was adjusted due to competitive pricing pressures and discontinued RX NARCAN sales, but volumes remain strong with 7% year-to-date growth [55][59] - Pricing in the NARCAN market has stabilized, with the majority of sales still coming from the public interest market [61][63] Question: Smallpox contract deliveries and future revenue recognition - A significant portion of the $400 million Smallpox contract will be recognized in 2025, with some revenue expected in Q4 2024 [65] Question: Asset sales and future site utilization - The company is evaluating further asset sales and site utilization, with a focus on reducing operating expenses while maintaining manufacturing capabilities [70][72] Question: Long-term EBITDA potential - The company has significantly reduced operating expenses and streamlined its site network, positioning itself for improved profitability, though specific 2025 guidance was not provided [74][75]

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 179.59%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.97 per share when it actually produced a loss of $2.32, delivering a surprise of -139.18%.Over the last four quar ...

| --- | --- | |----------------------------|-------| | | | | | | | | | | | | | Q3 2024 | | | Financial | | | Results | | | Update | | | November 6, 2024 | | | | | | | | | | | | Proprietary & Confidential | | PROPRIETARY AND CONFIDENTIAL Q3 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 300 Professional Drive Gaithersburg, MD 20879 Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA). The study will evaluate the safety and effic ...

Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) the type of information that the registrant treats as private or confidential. CREDIT AGREEMENT by and among WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Sole Lead Arranger, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Sole Book Runner, THE LENDERS THAT ARE PARTIES HERETO as the Lenders, EMERGENT BIOSOLUTIONS INC., EMERGENT BIODEFENSE OPERATION ...

LOS ANGELES, Oct. 25, 2024 (GLOBE NEWSWIRE) -- BlueOne Card, Inc. (OTCQX: BCRD) (“BlueOne Card,” the “Company”), a leading fintech provider of payment hub solutions and prepaid debit cards, today announced that it has entered into a definitive agreement to acquire equity interest of 60% in Millennium EBS, Inc. The transaction is valued at $12 million. This acquisition positions BlueOne Card to emerge as a prominent payment hub and prepaid debit card provider, significantly expanding its reach and capabiliti ...

Class Action Settlement Overview - The United States District Court for the District of Maryland has approved a proposed class action settlement benefiting purchasers of Emergent BioSolutions Inc common stock (NYSE: EBS) between March 10, 2020, and November 4, 2021 [1] - A hearing is scheduled for February 27, 2025, to determine the fairness and adequacy of the proposed $40 million settlement, the Plan of Allocation, and the approval of attorneys' fees and expenses [2] - The Settlement Class includes all persons or entities who purchased or acquired Emergent common stock during the Settlement Class Period, excluding certain individuals and entities such as Settling Defendants, their immediate families, and affiliates [3] Settlement Details and Claims - The proposed settlement resolves allegations that Settling Defendants made material misrepresentations and omissions concerning Emergent's business operations, reported results, and internal controls, leading to inflated stock prices during the Settlement Class Period [4] - Lead Plaintiffs allege that the revelation of Settling Defendants' fraud caused statistically significant stock declines, injuring investors [4] - Settlement Class Members must submit a Proof of Claim and Release Form by February 4, 2025, to be eligible for recovery from the Net Settlement Fund [5] Exclusion and Objection Procedures - Settlement Class Members who wish to exclude themselves from the Settlement Class must submit a request for exclusion by February 6, 2025 [6] - Members who do not exclude themselves can object to the Settlement, Plan of Allocation, or Lead Counsel's request for attorneys' fees and expenses by February 6, 2025 [7] - All members of the Settlement Class who do not request exclusion will be bound by any Judgment entered in the Action pursuant to the Settlement Stipulation [6]

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. Webcast & Conference Call Information Participants can access the conference call live via webcast. To join via telephone, please use the following dialin details: U.S. / New York: +1-646-968-2525 U.S ...

Ongoing support of the 'White House Challenge to Save Lives from Overdose' through workplace and public safety measures One-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities 20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by ...